이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Saniona 과거 수익 실적

과거 기준 확인 0/6

Saniona의 수입은 연평균 -16.9%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 11.8%의 비율로 증가했습니다. 매출은 연평균 13.7%의 비율로 감소해 왔습니다.

주요 정보

-16.9%

수익 성장률

-3.5%

EPS 성장률

Biotechs 산업 성장	0.7%
매출 성장률	-13.7%
자기자본 수익률	-305.6%
순이익	-402.2%
다음 실적 업데이트	29 Aug 2024

최근 과거 실적 업데이트

Recent updates

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

수익 및 비용 분석

Saniona 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:SANION 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	21	-83	77
31 Dec 23	17	-96	81
30 Sep 23	15	-108	52
30 Jun 23	12	-66	9
31 Mar 23	11	-100	113
31 Dec 22	15	-212	229
30 Sep 22	15	-334	330
30 Jun 22	15	-445	439
31 Mar 22	14	-461	450
31 Dec 21	10	-411	409
30 Sep 21	9	-326	352
30 Jun 21	9	-280	300
31 Mar 21	9	-200	225
31 Dec 20	8	-73	160
30 Sep 20	11	-25	113
30 Jun 20	9	-5	102
31 Mar 20	8	-1	95
31 Dec 19	7	-69	95
30 Sep 19	5	-96	110
30 Jun 19	49	-53	108
31 Mar 19	52	-52	115
31 Dec 18	55	-41	104
30 Sep 18	57	-32	89
30 Jun 18	17	-61	85
31 Mar 18	17	-56	79
31 Dec 17	21	-49	74
30 Sep 17	21	-47	74
30 Jun 17	68	-6	71
31 Mar 17	67	-2	67
31 Dec 16	75	2	69
30 Sep 16	71	10	56
30 Jun 16	23	-25	52
31 Mar 16	25	-21	46
31 Dec 15	14	-23	39
30 Sep 15	16	-23	41
30 Jun 15	19	-16	36
31 Mar 15	23	-10	33
31 Dec 14	22	-6	27
31 Dec 13	13	-1	14

양질의 수익: SANION 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SANION 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SANION 은(는) 수익성이 없으며 지난 5년 동안 연간 16.9% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SANION 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SANION 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 3% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SANION 현재 수익성이 없기 때문에 마이너스 자본 수익률( -305.58% )을 갖습니다.

Saniona 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

Recent updates

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - kr42.50

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - kr29.30

수익 및 비용 분석